loading page

Use of Targeted Agents to Treat Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in an Adolescent Patient
  • +1
  • Ashley Jean,
  • Alexandra Kovach,
  • Gordana Raca,
  • Jamie Stokke
Ashley Jean
Children's Hospital of Los Angeles

Corresponding Author:[email protected]

Author Profile
Alexandra Kovach
Children's Hospital of Los Angeles
Author Profile
Gordana Raca
Children's Hospital of Los Angeles
Author Profile
Jamie Stokke
Children's Hospital of Los Angeles
Author Profile

Abstract

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a generally indolent neoplasm of mature B lymphocytes that primarily affects older adults but rarely occurs in adolescents and young adults. We report a case of CLL/SLL in an 18-year-old patient treated with venetoclax, an orally bioavailable BCL-2 inhibitor, in combination with obinutuzumab, a humanized anti-CD20 monoclonal antibody. The patient experienced rapid clinical response and after one year of therapy had no evidence of residual disease by radiographical imaging and bone marrow evaluation. This finite, targeted therapeutic approach is an attractive option for future adolescent patients with CLL/SLL.